देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
MERCK CANADA INC
J05AR24
LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE
100MG; 300MG; 300MG
TABLET
DORAVIRINE 100MG; LAMIVUDINE 300MG; TENOFOVIR DISOPROXIL FUMARATE 300MG
ORAL
30
Prescription
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
Active ingredient group (AIG) number: 0360870001; AHFS:
APPROVED
2018-11-09
_DELSTRIGO_ _®_ _ (doravirine/lamivudine/tenofovir disoproxil fumarate) _ _Page 1 of 61_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DELSTRIGO ® d oravirine/lamivudine/tenofovir disoproxil fumarate tablets Tablets, 100 mg/300 mg/300 mg, oral Antiviral Agent Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7 www.merck.ca Date of Initial Authorization: November 9, 2018 Date of Revision: July 6, 2023 Submission Control Number: 266249 _DELSTRIGO_ _®_ _ (doravirine/lamivudine/tenofovir disoproxil fumarate) _ _Page 2 of 61 _ RECENT MAJOR LABEL CHANGES 1 INDICATIONS 07/ 2023 1.1 INDICATIONS, 1.1 Pediatrics 07/ 2023 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 07/ 2023 7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics 07/ 2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................... 5 4 DOSAGE AND ADMINISTRATION ................................................................................ 5 4.1 Dosing Considerations ...................................... पूरा दस्तावेज़ पढ़ें